AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy

Suman Kambhampati, Alireza Eghtedar, Christine McMahon, Stephane de Botton, Arnaud Pigneux, Brian Ball, Gautam Borthakur, Angela Volkert, Joanie Aasen Gausman, Kristen Baker, Graeme Hodgson, Erica Warlick, David Roth, Michael Kelly, Daniel Pollyea, Eytan Stein

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences